BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from human gastric juice that has been studied in laboratory animals for its potential to promote tissue healing, wound repair, and reduce inflammation, though it is not approved by any drug regulatory agency for human use.
Brief glance
The primary outcome is Recovery & Repair, but it's also used for Performance, Immune Support. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.
| Phase | Days | Dosage | Frequency |
|---|---|---|---|
| maintenance | 1 – 30 | 250 µg | Every day |
Estimation based on publicly available research; not derived from official prescribing guidance. Not medical advice — consult a qualified healthcare professional before beginning any dosing protocol.
Overview
BPC-157 is a synthetic 15-amino acid peptide derived from a protective protein in human gastric juice, known for its stability and regenerative effects in animal studies. Research shows it promotes tissue repair, wound healing, and protection in areas like the gut, joints, tendons, ligaments, and even the brain by enhancing cellular pathways and reducing inflammation. Primarily used as a premium research peptide, it is not FDA-approved for human use and is available through specialized vendors.
BPC-157, or Body Protection Compound 157, is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein in human gastric juice. It is stable in gastric environments and has been studied primarily in animal models for its potential to accelerate healing of wounds, tendons, muscles, ligaments, bones, and organs by activating pathways like VEGFR2 for angiogenesis, Akt-eNOS for nitric oxide production, and FAK-paxillin for cell migration, while modulating inflammation. Despite these preclinical findings suggesting regenerative and anti-inflammatory effects, BPC-157 lacks approval from any drug regulatory agency, including the FDA, for human use and is classified as an unapproved drug and prohibited substance by WADA and DoD lists. Limited human data exists, with most evidence confined to rodents where it demonstrates oral bioavailability and tissue repair promotion.
Benefits
BPC-157 promotes tissue regeneration, wound healing, and angiogenesis while reducing inflammation, with preclinical evidence supporting its use in repairing tendons, ligaments, muscles, and gastrointestinal lesions such as ulcers and irritable bowel syndrome.1,2,3,4 It enhances collagen synthesis and blood flow to injured areas, potentially aiding recovery from joint pain, osteoarthritis, and sports injuries in animal models and limited human observations.2,5 Additional effects include gut mucosa protection and neuroprotective properties against neuronal damage, though human clinical trials remain limited and inconclusive.3,6,7
Side effects
Common side effects of BPC-157 include mild injection site reactions such as itching, redness, swelling, or pain, along with headaches, nausea, dizziness, and fatigue, which are typically transient and resolve within hours to days.3,8,9 Rare but more serious reactions may involve fevers, rashes, vomiting, hives, blistering, muscle pain, or signs of allergic response, necessitating immediate discontinuation and medical consultation.3,9,10 Theoretical risks include pathologic angiogenesis potentially promoting tumor growth, overproduction of nitric oxide leading to anemia or altered drug metabolism, and immune responses from impurities or contamination in unregulated products.5,9,10 As BPC-157 lacks FDA approval for human use and sufficient clinical safety data, key considerations encompass using the lowest effective dose, rotating injection sites, monitoring for subjective changes, and avoiding in patients with cancer history or vascular disease due to unconfirmed long-term effects.5,9,10,11 No evidence of hepatotoxicity, nephrotoxicity, or cardiac damage appears in animal studies.9
Mechanisms of action
BPC-157 promotes healing by binding to VEGFR2 receptors on endothelial cells, triggering phosphorylation and activation of the Akt-eNOS pathway, which boosts nitric oxide production to dilate blood vessels and enhance blood flow to damaged tissues.10,12 This interaction also modulates Src and caveolin-1 phosphorylation, sustaining eNOS activity and nitric oxide release while stabilizing vascular structures against ischemic damage.10,12,13 Additionally, it activates pathways including FAK-paxillin for cell migration, JAK-2 for cell survival and growth, Egr-1 as a master regulator of repair genes, and ERK1/2 for cell proliferation, collectively fostering tissue regeneration.10,12 BPC-157 downregulates pro-inflammatory genes like Nos2 and NF-κB to curb excessive inflammation and oxidative stress, while upregulating antioxidants such as heme oxygenase-1 via cytoprotective signaling.10,12 These interconnected mechanisms create an optimal microenvironment for angiogenesis, cellular repair, and barrier integrity in preclinical models.10,12,13